Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 3013 Science Park Rd SAN DIEGO CA 92121-1101 |
Tel: | N/A |
Website: | https://www.gossamerbio.com |
IR: | See website |
Key People | ||
Faheem Hasnain Chairman of the Board, President, Chief Executive Officer, Co-Founder | Bryan M. Giraudo Chief Financial Officer, Chief Operating Officer | Caryn Peterson Executive Vice President - Regulatory Affairs |
Christian Waage Executive Vice President - Technical Operations and Administration | Richard Aranda Chief Medical Officer | Bob Smith Chief Commercial Officer |
Business Overview |
N/A |
Financial Overview |
For the fiscal year ended 31 December 2023, Gossamer Bio Inc revenues was not reported. Net loss decreased 22% to $179.8M. Lower net loss reflects research and development decrease of 18% to $119.4M (expense), Other income (expense) increase from $1.5M to $15.5M (income), Stock-based Compensation in R&D decrease of 35% to $15.9M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.71 to -$1.18. |
Employees: | 135 as of Feb 27, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $78.98M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$172.03M as of Dec 31, 2023 |
Net annual income (TTM): | -$179.82M as of Dec 31, 2023 |
Free cash flow (TTM): | -$159.16M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 225,582,250 as of Feb 27, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |